The Wayback Machine - http://web.archive.org./web/20160415051911/http://wn.com/SYK

Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual ...

Edit Stockhouse 14 Apr 2016
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer ... a dual SYK/JAK inhibitor for the treatment of B-cell malignanciesPresenting Author ... Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions....

Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 (Portola Pharmaceuticals Inc)

Edit Public Technologies 14 Apr 2016
Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer ... a dual SYK/JAK inhibitor for the treatment of B-cell malignancies Presenting Author ... Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions....

Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference

Edit Stockhouse 12 Apr 2016
SOUTH SAN FRANCISCO, Calif., April 12, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... IRAK ... Abstract #. 346 ... Location. Section 17 . Poster Board #. 2. AMPK ... The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN)....

Rigel Announces Presentations at Upcoming American Association of Cancer Research (AACR) Conference (Rigel Pharmaceuticals Inc)

Edit Public Technologies 12 Apr 2016
(Source. Rigel Pharmaceuticals Inc). SOUTH SAN FRANCISCO, Calif., April 12, 2016 /PRNewswire/ -- Rigel Pharmaceuticals, Inc ... IRAK ... Abstract #. 346. Presentation Title ... The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN)....

Osiris to Present 15 Advanced Clinical and Scientific Abstracts (Osiris Therapeutics Inc)

Edit Public Technologies 12 Apr 2016
(Source. Osiris Therapeutics Inc). Experts to host a variety of presentations at the Symposium on Advanced Wound Care & Wound Healing Society Spring Conference, April 13 - April 17, 2016, in Atlanta, Georgia. COLUMBIA, Md.--(BUSINESS WIRE)-- Osiris Therapeutics, Inc ... Osiris will be presenting a total of 15 abstracts ... The nine scientific studies demonstrate the characterization and benefits of placental and skin allografts. Dr ... Dr ... SYK)....

Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis ...

Edit Stockhouse 06 Apr 2016
C ... These programs include betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers.  Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions ... ....

Portola Pharmaceuticals Announces Presentation of Phase 3 APEX Study Results at International Society on Thrombosis and Haemostasis (ISTH) SSC Meeting 2016 on May 27, 2016 (Portola Pharmaceuticals Inc)

Edit Public Technologies 06 Apr 2016
(Source ... C ... These programs include betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions ... (noodl....

Stryker completes acquisition of Physio-Control International, Inc.

Edit Stockhouse 05 Apr 2016
Kalamazoo, Michigan - April 5, 2016 - Stryker Corporation (NYSE. SYK) announced today the completion of its previously announced acquisition of Physio-Control International, Inc. (Physio-Control).  Physio-Control develops, manufactures and markets monitors/defibrillators, automated external defibrillators (AEDs) and CPR-assist devices along with data management and support services ... Forward-looking statements ... Contacts ... ....

Stryker completes acquisition of Physio-Control International, Inc. (Stryker Corporation)

Edit Public Technologies 05 Apr 2016
(Source. Stryker Corporation). Kalamazoo, Michigan - April 5, 2016 - Stryker Corporation (NYSE. SYK) announced today the completion of its previously announced acquisition of Physio-Control International, Inc. (Physio-Control). Physio-Control develops, manufactures and markets monitors/defibrillators, automated external defibrillators (AEDs) and CPR-assist devices along with data management and support services ... Forward-looking statements....

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with ...

Edit Stockhouse 04 Apr 2016
About Andexanet Alfa ... These programs include betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions ... ....

Portola Pharmaceuticals Enters Into Clinical Collaboration Agreement with Daiichi Sankyo to Develop Andexanet Alfa with Edoxaban in Japan (Portola Pharmaceuticals Inc)

Edit Public Technologies 04 Apr 2016
(Source ... These programs include betrixaban, an oral, once-daily Factor Xa inhibitor; andexanet alfa, a recombinant protein designed to reverse the anticoagulant effect in patients treated with an oral or injectable Factor Xa inhibitor; and cerdulatinib, a Syk/JAK inhibitor in development to treat hematologic cancers. Portola's partnered program is focused on developing selective Syk inhibitors for inflammatory conditions ... (noodl....

Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP

Edit Stockhouse 01 Apr 2016
 Research has shown that inhibiting SYK with fostamatinib may reduce the destruction of red blood cells.  ... The company's current clinical programs include fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP; a Phase 2 clinical trial for autoimmune hemolytic anemia (AIHA); and a Phase 2 clinical trial for IgA nephropathy (IgAN)....

Rigel Completes Enrollment of FIT Phase 3 Program for Fostamatinib in ITP (Rigel Pharmaceuticals Inc)

Edit Public Technologies 01 Apr 2016
(Nasdaq.RIGL) today announced it has completed enrollment for both studies in the FIT Phase 3 clinical program of fostamatinib, its oral spleen tyrosine kinase (SYK) inhibitor, in immune thromboycytopenic purpura (ITP) ... Research has shown that inhibiting SYK with fostamatinib may reduce the destruction of red blood cells....
×